Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
vMCO-010 in Stargardt Disease
NCT05417126Phase 2Completed
- Sponsor
- Nanoscope Therapeutics
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of sonpiretigene isteparvovec in Stargardt disease (STGD), sponsored by Nanoscope Therapeutics. Started Jul 2022; status: completed.
02
Drugs
sonpiretigene isteparvovec
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT05417126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417126.